Back to Results

AAML1531


Title Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Therapeutic Area Leukemias (Pediatric)
Principal Investigator Jason Law, MD
Min Age 0 Years
Max Age 4 Years
Gender Male or Female
Contact NCCCR
617-632-3264
NCCCR@tuftsmedicalcenter.org
More Information https://clinicaltrials.gov/ct2/show/NCT02521493?term=AAML1531&draw=2&rank=1

Overview

The overall goals of this study are to:

  • To find out if subjects with down syndrome and standard risk acute myeloid leukemia can be treated with less treatment and still have successful outcomes.
  • To find out if subjects with down syndrome and high risk acute myeloid leukemia can be successfully treated with stronger chemotherapy.

Study Details

Inclusion Criteria

  • Children with down syndrome (trisomy 21)
  • Newly diagnosed acute myeloid leukemia or myelodysplastic syndrome

  •  

     

 

Exclusion Criteria

  • No prior treatment for leukemia

Study Requirements

Subjects will come to the hospital to receive courses of chemotherapy. Usually, all subjects with DS AML get the same amount of chemo. In this study, subjects that respond to the first course of chemo will be given less chemo in later courses in the hope of reducing side effects. And subjects that do not respond to the first course of chemo will be given more chemo in later courses in the hope of improving outcomes.